Diagnóstico y tratamiento | 23 JUN 19

Piodermia gangrenosa

Es importante que todos los médicos estén bien informados sobre la piodermia gangrenosa y la tengan en cuenta cuando evalúan pacientes con úlceras
8
18
Autor: George C, Deroide F, Rustin M Clinical Medicine 2109;3:324-328
INDICE:  1. Página 1 | 2. Referencias bibliográficas
Referencias bibliográficas

1 Langan SM , Groves RW , Card TR , Gulliford MC . Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study . J Invest Dermatol 2012 ; 132 : 2166 – 70.
2 Ahronowitz I , Harp J , Shinkai K . Etiology and management of pyoderma gangrenosum: a comprehensive review . Am J Clin Dermatol 2012 ; 13 : 191 – 211 .
3 Binus AM , Qureshi AA , Li VW , Winterfield LS . Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients . Br J Dermatol 2011, 165: 1244– 50.
4 Alberts JH , Sams HH , Miller JL et al. Familial ulcerative pyoderma gangrenosum: a report of 2 kindred . Cutis 2002; 69 : 427 – 30 .
5 Schwaegerle SM , Bergfeld WF , Senitzer D et al . Pyoderma gangrenosum: A review . J Am Acad Dermatol 1988 ; 18 : 559 – 68 .
6 Sassolas B , Le Ru Y , Plantin P et al . Pyoderma gangrenosum with pathergic phenomenon in pregnancy . Br J Dermatol 2000 ; 142 : 827 – 8 .
7 Graham JA , Hansen KK , Rabinowitz LG et al . Pyoderma gangrenosum in infants and children . Pediatr Dermatol 1994;  11: 10– 7.
8 Sakiyama M , Kobayashi T , Nagata Y et al . Bullous pyoderma gangrenosum: A case report and review of the published work .J Dermatol 2012 ; 39 : 1010 – 5 .
9 Weenig RH , Davis MD , Dahl PR et al . Skin ulcers misdiagnosed as pyoderma gangrenosum . N Engl J Med 2002 ; 347 : 1412 – 8 .
10 Perry HO , Winkelmann RK. Bullous pyoderma gangrenosum and leukemia . Arch Dermatol 1972 ; 106 : 901 – 5 .
11 Shankar S , Sterling JC , Rytina E . Pustular pyoderma gangrenosum. Clin Exp Dermatol 2003 ; 28 : 600 – 3 .
12 Wilson-Jones E , Winkelmann RK. Superficial granulomatous pyoderma: a localized vegetative form of pyoderma gangrenosum. J Am Acad Dermatol 1988 ; 18 : 511 – 21 .
13 Wu XR , Mukewar S , Kiran RP et al . Risk factors for peristomal pyoderma gangrenosum complicating inflammatory bowel disease. J Crohns Colitis 2013; 7 : e171 – 7 .
14 Bennett ML , Jackson JM , Jorizzo JL et al . Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from two institutions. Medicine (Baltimore) 2000; 79 : 37 – 46 .
15 Erdi H , Anadolu R , Pis¸kin G et al . Malignant pyoderma: A clinical variant of pyoderma gangrenosum . Int J Dermatol 1996; 35 : 811 – 3 .
16 Callen JP, Jackson JM. Pyoderma gangrenosum: an update. Rheum Dis Clin North Am 2007; 33: 787 – 802 .
17 Wang JY , French LE , Shear NH , Amiri A , Alavi A . Drug-induced pyoderma gangrenosum: a review . Am J Clin Dermatol 2017 ; 19 : 67 – 77 .
18 Braun–Falco M , Kovnerystyy O , Lohse P , Ruzicka T . Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) – a new autoinflammatory syndrome distinct from PAPA syndrome . J Am Acad Dermatol 2012 ; 66 : 409 – 15 .
19 Lindor NM , Arsenault TM , Solomon H , Seidman CE , McEvoy MT . A new autosomal dominant disorder of pyogenic sterile arthritis, pyoderma gangrenosum, and acne: PAPA syndrome . Mayo Clinic Proc 1997 ; 72 : 611 – 5 .
20 Marzano AV , Trevisan V , Gattorno M et al . Pyogenic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PAPASH): a new autoinflammatory syndrome associated with a novel mutation of the PSTPIP1 gene . JAMA Dermatol 2013 ; 149 : 762 – 4 .
21 Magro CM , Kiani B , Li J et al. Clonality in the setting of Sweet’s syndrome and pyoderma gangrenosum is not limited to underlying myeloproliferative disease . J Cutan Pathol  2007 ; 34 : 526 – 34 .
22 Oka M , Berking C , Nesbit M et al. Interleukin–8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts . Lab Invest 2000; 80 : 595 – 604 .
23 Oka M. Pyoderma gangrenosum and interleukin 8. Br J Dermatol 2007;157 : 1279 – 81
24 Marzano AV , Fanoni D , Antiga E et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet’s syndrome . Clin Exp Immunol  2014 ; 178 : 48 – 56 .
25 Bister V , Makitalo L , Jeskanen L et al. Expression of MMP–9, MMP–10 and TNF–alpha and lack of epithelial MMP–1 and MMP–26 characterize pyoderma gangrenosum . J Cutan Pathol 2007 ; 34 : 889 – 98 .
26 Brooklyn TN , Williams AM , Dunnill MG et al. T–cell receptor repertoire in pyoderma gangrenosum: evidence for clonal expansions and trafficking . Br J Dermatol 2007; 157 : 960 – 6 .
27 Tallon B , Corkill M. Peculiarities of PAPA syndrome . Rheumatology (Oxford) 2006 ; 45: 1140 – 3.
28 Weedon D. Weedon’s Skin pathology, 3rd ed . Elsevier , 2010 : 195 –244 .
29 Weenig RH , Davis MD , Dahl PR et al . Skin ulcers misdiagnosed as pyoderma gangrenosum . N Engl J Med 2002 ; 347 : 1412 – 8 .
30 Su WP , Davis MD , Weenig RH , Powell FC , Perry HO . Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria . Int J Dermatol 2004 ; 43: 790 – 800 .
31 Maverakis E , Ma C , Shinkai K et al . Diagnostic criteria of ulcerative pyoderma gangrenosum. A Delphi consensus of international experts . JAMA Dermatol 2018 ; 154  461 – 6 .
32 Ormerod AD , Thomas KS , Craig FE et al . Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial . BMJ 2015 ; 350 : h2958 .
33 Brooklyn TN , Dunnill MG , Shetty A et al . Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006 ; 55 : 505 – 9 
34 Miller J , Yentzer BA , Clark A , Jorizzo JL , Feldman SR . Pyoderma gangrenosum: a review and update on new therapies . J Am Acad Dermatol 2010; 62 : 646 – 54.
35 Wenzel J, Gerdsen R , Phillipp–Dormston W , Bieber T , Uerlich M .Topical treatment of pyoderma gangraenosum . Dermatology 2002 ; 205 : 221 – 3 .
36 Reichrath J , Bens G , Bonowitz A , Tilgen W . Treatment recommendations for pyoderma gangrenosum: an evidence–based review of the literature based on more than 350 patients . J Am Acad Dermatol 2005; 53: 273– 83.
37 Agarwal A , Andrews JM. Systematic review: IBD–associated pyoderma gangrenosum in the biologic era, the response to therapy. Aliment Pharmacol Ther 2013 ; 38 : 563 – 72 .
38 Brooklyn TN , Dunnill MG , Shetty A et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo-controlled trial. Gut 2006 ; 55 : 505 – 9
39 Arguelles-Arias F , Castro-Laria L , Lobaton T et al . Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease . Dig Dis Sci 2013; 58 : 2949 – 54 
40 Fonder MA , Cummins DL , Ehst BD , Anhalt GJ , Meyerle JH .Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds 2006 ; 5 : e8 .
41 Charles CA , Leon A , Banta MR , Kirsner RS . Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series . Int J Dermatol 2007; 46 : 1095 – 9 .
42 Fahmy M , Ramamoorthy S , Hata T , Sandborn WJ . Ustekinumab for peristomal pyoderma gangrenosum . Am J Gastroenterol 2012 ; 107 : 794 – 5 .
43 Brenner M , Ruzicka T , Plewig G , Thomas P , Herzer P . Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin–1 receptor antagonist anakinra .Br J Dermatol 2009 ; 161 : 1199 – 201
44 Geusau A , Mothes–Luksch N , Nahavandi H et al . Identification of a homozygous PSTPIP1 mutation in a patient with a PAPA–like syndrome responding to canakinumab treatment . JAMA Dermatol 2013 ; 149 : 209 – 15 .

 

Comentarios

Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí

Contenidos relacionados
Los editores le recomiendan continuar con las siguientes lecturas: